Meeting
2015 ASCO Annual Meeting
A phase 1 study of INCB040093, a PI3Kδ inhibitor, alone or in combination with INCB039110, a selective JAK1 inhibitor: Interim results from patients (pts) with relapsed or refractory (r/r) classical Hodgkin lymphoma (cHL).
Authors
Andres Forero-Torres
University of Alabama at Birmingham, Birmingham, AL
Andres Forero-Torres , Paul M. Barr , Catherine S. Magid Diefenbach , Taimur Sher , Richard Schaub , Li Zhou , Jennifer Pulini , Lance Leopold , Matthew A. Spear , Moshe Talpaz , Tycel Jovelle Phillips
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lymphoma and Plasma Cell Disorders
Track
Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
Sub Track
Lymphoma
Clinical Trial Registration Number
NCT01905813
Citation
J Clin Oncol 33, 2015 (suppl; abstr 8558)
DOI
10.1200/jco.2015.33.15_suppl.8558
Abstract #
8558
Poster Bd #
376
Abstract Disclosures
Similar Posters
Poster
2015 ASCO Annual Meeting
Interim analysis of a phase I study of INCB040093, a PI3Kδ inhibitor, alone or in combination with INCB039110, a selective JAK1 inhibitor, in patients (pts) with relapsed or refractory (r/r) B-cell malignancies.
First Author: Tycel Jovelle Phillips
Poster
2022 ASCO Annual Meeting
SHR2554, an enhancer of zeste homolog 2 (EZH2) inhibitor, in relapsed or refractory (r/r) mature lymphoid neoplasms: A first-in-human phase 1 study.
First Author: Yuqin Song
Poster
2021 ASCO Annual Meeting
Phase 1 expansion trial of the LSD1 inhibitor seclidemstat (SP-2577) with and without topotecan and cyclophosphamide (TC) in patients (pts) with relapsed or refractory Ewing sarcoma (ES) and select sarcomas.
First Author: Damon R. Reed
Poster
2018 ASCO Annual Meeting
Phase I/II study to evaluate the safety and efficacy of tenalisib, a novel PI3K δ/γ dual inhibitor in combination with pembrolizumab in patients with relapsed/refractory classical Hodgkin lymphoma.
First Author: Rod Ramchandren